Pharmacological characterization of cannabinoid receptor activity in the rat‐isolated ileum myenteric plexus‐longitudinal muscle preparation
Authors:
Open Access
- 29 March 2010
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (8) , 1608-1622
Abstract
Background and purpose: Cannabinoid effects on intestinal transit are commonly evaluated in rats. We characterized the cannabinoid receptors mediating the inhibitory effect of 5‐(1,1‐dimethylheptyl)‐2‐[5‐hydroxy‐2‐(3‐hydroxypropyl)‐cyclohexyl]‐phenol (CP 55,940), (R)‐(+)‐[2,3‐dihydro‐5‐methyl‐3‐(4‐morpholinylmethyl)pyrrolo[1,2,3‐de]‐1,4‐benzoxazin‐6‐yl]‐1‐naphthalenylmethanone mesylate (WIN 55,212‐2), arachidonylethanolamide (AEA) and Δ9‐tetrahydrocannabinol (Δ9‐THC) on contractions of the rat ileum myenteric plexus‐longitudinal muscle (MPLM) preparation.Experimental approach: The interaction of each agonist was examined with the CB1and CB2receptor antagonist rimonabant and SR 144,528 respectively, on contractions elicited by electrical field stimulation (EFS) or exogenous ACh. The interaction of AEA with capsazepine, a TRPV1receptor antagonist, was also investigated.Key results: EFS with single and trains of pulses evoked neurogenic ACh‐mediated twitch and rebound contractions respectively. The rank order of potency for inhibition was CP 55,940 = WIN 55,212‐2 > AEA > Δ9‐THC and AEA > WIN 55,212‐2 =Δ9‐THC = CP 55,940 respectively. The stereoisomer WIN 55,212‐3 was without effect. Rimonabant antagonized the inhibition of the twitches with pKBvalues of around 8.60, but only antagonized rebound contractions induced by WIN 55,212‐2, AEA and Δ9‐THC, with pA2values of around 6.80. Rimonabant increased the twitches but inhibited the rebound contractions. Contractions to exogenous ACh were not altered. These observations extended to the guinea pig ileum MPLM.Conclusions and implications: The rat MPLM contains CB1receptors and at least two non‐CB1‐non‐CB2‐non‐TRPV1receptors attenuating EFS‐evoked ACh‐mediated contractions in an EFS frequency‐dependent pre‐synaptic and stereo‐specific manner. Augmentation of the twitches by rimonabant may be through antagonism of an endocannabinoid tone or inverse agonism, whereas inhibition of the rebound contractions involved partial agonism.Keywords
This publication has 60 references indexed in Scilit:
- Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated ratsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Novel cannabinoid receptorsBritish Journal of Pharmacology, 2007
- Investigation on the relationship between cannabinoid CB1and opioid receptors in gastrointestinal motility in miceBritish Journal of Pharmacology, 2006
- Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal stripsBritish Journal of Pharmacology, 2006
- Inverse agonism and neutral antagonism at cannabinoid CB1 receptorsLife Sciences, 2005
- Inhibitory effect of ginger (Zingiber officinale) on rat ileal motility in vitroLife Sciences, 2004
- Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexusJournal of Comparative Neurology, 2002
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994